Haraoka M, Matsumoto T, Mizunoe Y, Takahashi K, Kubo S, Koikawa Y, Tanaka M, Sakamoto Y, Sakumoto M, Nagafuji T
Department of Urology, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Chemotherapy. 1995 May-Jun;41(3):208-13. doi: 10.1159/000239346.
Renal scarring, which occurs following refluxing pyelonephritis, is considered to be involved in the development of reflux nephropathy. Prevention of renal scar formation requires immediate initiation of antimicrobial treatment; treatment delay results in renal scarring. We demonstrate that Ebselen, an antioxidant agent, given at a dose of 15 mg/kg twice a day prevents renal scarring in rats following direct renal parenchymal bacterial inoculation. In addition, using an ascending pyelonephritis model, which clinically resembles refluxing pyelonephritis in humans, we show that when initiation of antimicrobial treatment was delayed, coadministration of Ebselen prevents renal scar formation. These results show that Ebselen is effective in preventing renal scarring and suggest that the clinical use of this drug may prevent renal scar formation following pyelonephritis and progression to reflux nephropathy.
反流性肾盂肾炎后发生的肾瘢痕形成被认为与反流性肾病的发展有关。预防肾瘢痕形成需要立即开始抗菌治疗;治疗延迟会导致肾瘢痕形成。我们证明,以每天两次15mg/kg的剂量给予抗氧化剂依布硒仑可预防大鼠直接肾实质细菌接种后的肾瘢痕形成。此外,使用一种临床上类似于人类反流性肾盂肾炎的上行性肾盂肾炎模型,我们发现当抗菌治疗开始延迟时,联合给予依布硒仑可预防肾瘢痕形成。这些结果表明依布硒仑在预防肾瘢痕形成方面有效,并提示该药物的临床应用可能预防肾盂肾炎后的肾瘢痕形成及进展为反流性肾病。